Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. Smoldering myeloma is associated with a higher disease burden and higher risk of progression to active disease than MGUS. The management of these precursor conditions remains unclear and the optimal timing of therapy in multiple myeloma has been a subject of debate. Whilst it would be useful to identify high-risk and asymptomatic individuals that could benefit from therapy to prevent progression to multiple myeloma, there is currently no evidence supporting the use of asymptomatic screening in clinical practice.
In this exclusive podcast recorded at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, and Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavik, Iceland, explore the benefits and risks of screening for multiple myeloma precursor conditions, presenting the design and findings of the iStopMM (NCT03327597) and PROMISE (NCT03689595) studies. Dr Ghobrial and Prof. Kristinsson talk on emerging technologies to identify patients with myeloma precursor conditions and question the clinical significance of MGUS and smoldering myeloma, commenting on the mental impact of screening.
Recent updates in CML: treatment strategies, clinical trials, and novel agents
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
iwAL 2022 Session II: Novel treatment strategies in ALL
The role of the innate immune system in MDS
iwAL 2022 Session I: The standard of care in AML in 2022
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
ISA 2022: meeting highlights and recent updates in amyloidosis
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
iwMDS 2022: Key highlights
Identifying high-risk myeloma and improving treatment strategies in these patients
Improving the efficiency of drug approvals in MDS
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
The need for more effective first-line therapies in MDS
Myeloma 2022: day two highlights
The promise of CAR-T therapy in CLL and challenges in the field
Clonal hematopoiesis and pre-MDS states
T-cell engagers in multiple myeloma: current challenges and future outlooks
High-risk MDS: unmet needs and future treatment approaches
The importance of patient-reported outcomes in CAR-T recipients
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.